Skip to content

Diclofenac vs. Ropivacaine for Cesarean Section

The Analgesic Efficacy of Continuous Wound Instillation With Diclofenac or Ropivacaine Following Cesarean Section: a Randomized, Double-blind, Placebo Controlled Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00801528
Enrollment
75
Registered
2008-12-03
Start date
2008-04-30
Completion date
2008-12-31
Last updated
2010-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section

Keywords

ropivacaine, diclofenac, local anesthetic instillation

Brief summary

A prospective, randomized, double blind study designed to investigate analgesic efficacy of wound infusion using diclofenac or ropivacaine following Cesarean section performed via a Pfannenstiel incision.

Detailed description

Study Objective: To assess the analgesic efficacy of diclofenac or ropivacaine when administered via wound infusion. Design: Prospective, randomized, double-blind, placebo-controlled study. Setting: Large referral hospital. Patients: 75 women recovering from Cesarean section performed via a Pfannenstiel incision. Interventions: On completion of the surgical procedure, a 15 cm 19G infusion catheter (PAINfusor™, Baxter) will be placed below the fascia. According to a computer generated randomization schedule, patients will be divided into one of three treatment groups (n = 25). * In Group Control water for injection will be administered. * In Group Ropivacaine 0.2 % ropivacaine will be administered. * In Group Diclofenac diclofenac (300 mg/240 ml of water for injection) will be administered. During the first 6 postoperative hours, a co-investigator will administer rescue analgesia (10 ml bolus of infusion drug or rescue morphine). Thereafter, the catheter will be connected to an elastometric pump (LV 10 Infusor, Baxter) filled with either water for injection, ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection). The fluid will be administered as a constant infusion rate (10 mL/hr). Continuous wound infusion will be continued for the subsequent 18 postoperative hours. During this 18 hour period, subcutaneous morphine 4 mg will be administered on patient request for additional analgesia. Measurements and Main Results: The following parameters will be assessed and recorded: 1. Demographic data 2. Surgical milestones(Anesthetic time, surgical time etc). 3. Incidence of failed intrathecal anesthesia 4. VAS for pain every 15 min during first 6 postoperative hours 5. Time to first pain (intrathecal anesthesia to VAS \> 60 mm) 6. Number of infusion events (10 mL and 5 mL) 7. Rescue morphine administration during first 6 postoperative hours. 8. Subcutaneous morphine administration during subsequent 18 postoperative hours. 9. VAS for pain. 10. The incidence of nausea and vomiting. 11. Patient satisfaction at 24 hours, postoperatively.

Interventions

DRUGRopivacaine, Diclofenac, Water for injection

Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.

Sponsors

Meir Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Patients undergoing Cesarean section

Exclusion criteria

A history of clinically significant disease: * cardiovascular * pulmonary * hepatic * renal * neurologic * psychiatric * metabolic disease

Design outcomes

Primary

MeasureTime frame
1)Pain intensity 2)Rescue analgesia requirements24 hours

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026